The author's conclusion that "... frozen section di agnosis of pelvic lymph nodes .... is more sensitive for the diagnosis of prostate carcinoma in pelvic lymph nodes than is MRI because more than half of the metastases are smaller than the 1-cm resolution limit of the MRI," may be misleading and is not correct.
The upper limit of the spatial resolution of magnetic resonance imaging (MRI) and computed tomography (CT) is m uch smaller than 1 cm. It depends on many factors, such as field of view, matrix size, slice thickness, image quality (signal-to-noise ratio, motion artifacts) and contrast between the object and surrounding structures. Using a three-dimensional imaging technique, we achieved an in-plane resolution of 1.3 mm X 1 mm and were able to visualize lymph nodes with a diameter of 4 mm. 2 Also, the literature search on imaging techniques is incomplete. The reviewed number of articles on CT and MRI is far too low; for example, the review does not in clude the article by Rifkin et al.,3 which includes more patients (185) investigated with MRI than the compilated data of the articles cited by the author. In this series, the sensitivity was only 4%.
In general, it is believed that MRI is equal to CT for lymph node imaging. The advantage of CT over MRI is that fine-nee die aspiration of a lymph node mass may be more easy to perform. In contrast to lymphangiography, in which métastasés are visible as filling defects of 4 mm or more in diameter,4 MRI and CT do not allow direct visualization of lymph node métastasés. The main criteria to assess the presence of lym ph node métastasés is the axial diameter of the lymph node. Perhaps the author con fused "resolution lim it'' with w hat is considered as the upper limit of a norm al sized lym ph node. However, crite ria for positive lymph nodes are arbitrary. In the cited articles, the upper limit of norm al varies from 1 cm 5,6 to 1.5 cm.7,8 There is a general tendency to lower the upper limit of normal. Recently, Vinnicombe et al.,9 who found that only 2% of norm al lymph nodes have a maximum short axis diameter of larger than 1 cm, suggested that the sensitivity of CT in depicting lymph nodes may be improved by adopting lower limits of normal. These may become 7 mm for internal iliac, 8 m m for obturator, 9 mm for com m on iliac, and 10 m m for external iliac lymph nodes. Using a three-dimensional imaging technique, we could add the shape of the lymph node in the judgment; round nodes with a diameter of 8 m m and an index of 0.8 (shortest axial diam eter divided by the long axis) or less were considered abnormal. W ith these criterion, the fig ures for sensitivity, specificity, and accuracy were 58%, 96%, and 92% in 62 patients (data presented at the 81st Annual Meeting of the Radiologic Society of North America, Nov-Dee, 1995). Van Poppel et al.10 consider even lymph nodes of 6 m m in diam eter on CT to be positive. Calculated figures for sensitivity, specificity, and accuracy were 77.8%, 96.6%, and 93.7%, respectively. W hen fineneedi e aspiration biopsy was performed to evaluate sus pected nodes, the calculated figures were 77.8%, 100%, and 96.5%, respectively. These figures are unique and may be not representative for imaging in general.
However, the argum ent that frozen section is more sensitive than CT or MRI does not implicate that there is no place for imaging as is suggested in the article by Davis.1 Lymph node métastasés detected by imaging will considerably save financial costs, morbidity, hospital stay, and patient discomfort. However, only 10% of pa tients who are candidates for surgical cure have m eta static lymph node disease.11,12 Therefore, cross-sectional imaging is not indicated for all patients. It should be re stricted for patients who are at high risk for having lymph node métastasés depending on prostate specific antigen, stage, and the Gleason biopsy score. Wolf et al. 13 have estimated that w hen the sensitivity of imaging was 36% (baseline derived from literature), imaging would be ben eficial w hen the probability of m étastasés was 32% and 1004 CANCER March 1,1996 / Volume 77 / Number 5 when suspected lymph nodes were confirmed by fineneedle aspiration biopsy.
In conclusion, imaging is still of value in a selected group of patients who are at high risk for lymph node métastasés to prevent them from an unnecessaiy opera tion. In my opinion, in this group of patients, the upper limit of normal should be less than 1 cm. Gerrit J. Jager, M.D.
D epartm ent o f Radiology University Hospital Nijmegen Nijmegen, The Netherlands
Author Reply I thank Dr. Jager for his comments. He is correct regard ing my confusion between the spatial resolution limit of the imaging technique and the criteria for metastasis (the axial diameter of the lymph node). The purpose of my study was to assess the diagnostic efficiency of fro zen section and then com pare the results with the only other modality available for the direct assessm ent of lymph node métastasés prior to pro statecto m y -im aging.
I did miss the 1990 article by Rifkin et al.,1 which indicates that magnetic resonance imaging and com puted tomography had high specificity (96%) but very low sensitivity (4%) for the diagnosis of lymph node métasta sés "because neither technique has the ability to identify microscopic spread of disease."1 In 1995, using either a 4-mm resolution limit for lymphangiography or a 6-mm limit for computed tomography, the best imaging tech niques cited by Dr. Jager, 18 of 39 or 22 of 39 patients in my series2 still would not have been detected due to the microscopic size of their métastasés below these respec tive resolution limits. Accepting Dr. Jager's criticism, I would change the conclusion of the paper to "Frozen section analysis is more sensitive for the diagnosis of prostate carcinoma in pelvic lymph nodes than are im aging techniques because 46% of the métastasés in our series are smaller than the lowest (4 mm) resolution limit of the imaging techniques to be reported by Barentsz et a l/'2 Imaging is of value in identifying patients who are at high risk for lymph node métastasés to prevent them from an unnecessaiy operation.3 Regardless of imaging tech nique or user, with an upper limit of normal lower than 1 cm, half of our patients with métastasés would still be missed and we are therefore unable to identify them in advance of lymphadenectomy.
The rapid changes taking place in both the diagnosis and treatment of prostate cancer are reflected in editori als and articles concerned with prostate specific antigen (PSA), biopsy grade, and treatment variables in the litera ture3-0 concurrent with the submission and publication of my paper. Imagers face the same dilemma as surgeons; how to select patients who will benefit by use of a proce dure. Strategies for detecting lymph node métastasés,7,(1 including imaging with or without fine-needle aspiration of "positive" lymph nodes and two-stage (open or laparascopic) lymphadenectomy, attempt to preselect patients at risk for lymph node métastasés by means of PSA, bi opsy grade, and clinical staging.
Can current clinical or laboratory parameters preselect patients who are at risk for lymph node métastasés? Using PSA levels and biopsy grade, we have been unable, retro spectively, to differentiate false-negative frozen-section pa tients (microscopic lymph node disease) from tine positive patients (unpublished data). Only at the extremes of PSA and grade can we predict lymph node metastases with greater efficiency than by frozen section and, for the major ity of our patients, there is no relationship between PSA and biopsy grade, and size of the metastasis. Metastasis does not necessarily result in lymph node enlargement.
As prostate cancer is diagnosed "earlier," I anticipate tliat a greater proportion of metastases will be occult,9 for the diagnosis of which current routine clinical laboratory tests and imaging are inadequate. The application of new diagnostic technology (such as polymerase chain reaction amplification10 for the detection of currently occult can cer cells in the blood stream or tissues obtained with minimally or noninvasive techniques with imaging local ization) is needed for the accurate and cost-effective stag ing and treatm ent of prostate cancer.
